Featured
Philips recovers from US trade tariffs hit
Gene Therapy Jul 28, 2026
Tumor Watch Jul 28, 2026
Trial Moves Jul 27, 2026
Philips recovers from US trade tariffs hit on medical devices with a €186 million refund,...
Bispecific antibodies are emerging immunotherapy for relapsed lymphoma and leukemia, offering a viable option when...
Heart failure management is shifting as pharmacists take on a larger role. Discover how they...
Read our latest NF Research articles.
Edwards sees boost in heart valve sales driven by increasing demand for TAVR devices and...
Explore the 2026 pulmonary embolism guidelines released by the American Heart Association and ACC, detailing...
Learn practical drink spiking prevention tips from pharmacists, including how OTC test strips work and...
Philips recovers from US trade tariffs hit on medical devices with a €186 million refund, nearly half of its net income, containing medical devices keyword.
Philips recovers from US trade tariffs hit on medical devices with a €186 million refund, nearly half of its net...
Freenome wins approval for cancer blood test, a new screening method for colorectal cancer diagnosis.
Johnson & Johnson gets FDA approval for Ottava robot to compete with da Vinci in soft tissue surgery systems.
Philips secures FDA approval for a new pulse oximeter addressing racial bias with improved accuracy across skin tones.
Tempus AI agrees to buy Personalis for $1.5 billion to enhance cancer diagnostics and treatment selection with molecular residual disease...
Edwards sees boost in heart valve sales driven by increasing demand for TAVR devices and newer treatments.
Dexcom joins the FDA’s digital health pilot program to accelerate innovative medical technologies with real-world data and faster approvals.
US adult obesity rates climbed to 41% between 1999 and 2023. New data reveals severe obesity doubling and abdominal obesity...
Explore the latest breast cancer treatment developments and the challenges of sequencing antibody-drug conjugates to optimize patient outcomes in oncology.
Bispecific antibodies are emerging immunotherapy for relapsed lymphoma and leukemia, offering a viable option when CAR T‑cell treatment isn’t possible,...